The nutrition and supplement market is experiencing a wave of strategic consolidation. Over the past 18 months, we’ve tracked $8.3B in announced M&A activity involving nutrition brands, with valuations reaching 8-12x EBITDA for high-growth, clinically-validated platforms.
Who’s Buying?
Strategic Acquirers
- Major CPG Players: PepsiCo, Nestlé, Unilever acquiring premium supplement brands for distribution and portfolio expansion
- Pharma & Healthcare: Pfizer, Abbott, Thorne expanding into consumer wellness
- Private Equity: KKR, Blackstone, Apollo investing in platform consolidators
Deal Patterns
Category-Specific Roll-Ups: PE funds are building “roll-up” platforms by acquiring 3-5 complementary brands, combining back-office functions, and leveraging distribution synergies for 25-40% margin improvement.
Strategic Acquisitions: Major CPG players acquiring brands for access to premium positioning, clinical evidence, and D2C capabilities not available through organic development.
International Expansion: Nutrition brands with strong US traction are attractive acquisition targets for international CPG/pharma players seeking market entry.
Exit Valuation Drivers
Recent acquisitions demonstrate that exit multiples are heavily influenced by:
| Factor | Impact |
|---|---|
| Revenue Growth (YoY) | +2x multiple per 10% incremental growth |
| Gross Margin | +1x multiple per 10% incremental margin |
| Clinical Evidence | +2-3x multiple premium vs. commodity |
| Brand Equity & Distribution | +1.5-2x multiple for proprietary channels |
| Team Strength | +0.5-1x multiple for experienced founders |
Optimal Exit Timing
Companies with $10M+ revenue, 50%+ YoY growth, and >60% gross margins are acquisition targets in the current environment. Three optimal exit windows:
- Series B/C Milestone ($10-30M revenue, high growth, clinical differentiation)
- Post-Scale Phase ($30-100M revenue, proven business model, operational excellence)
- Category Leadership ($100M+ revenue, market consolidator, platform potential)
Strategic Recommendations
If you’re considering an exit:
- Build your clinical story early — starts valuation conversation at +2-3x multiple
- Establish institutional partnerships — validates demand and reduces buyer risk perception
- Optimize operations before exit — demonstrates scalability and profitability
- Create competitive tension — multiple buyer interest drives 20-30% valuation uplift
The market is active, valuations are strong, and windows of opportunity remain open for differentiated nutrition platforms.